GRCE,ACOG,SLGL,ETON,SNWV,HROW,CDXS Stock Price and Quote

Peers: MIST DMAC TENX HRTX CVKD CALC ICU UNCY ZVRA PCSA

Index	-
Market Cap	40.28M
Enterprise Value	26.52M
Income	-20.22M
Sales	0.00M
Book/sh	2.96
Cash/sh	0.65
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	May 06, 2011

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.65
P/C	2.93
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	11.47
Current Ratio	11.47
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.18
EPS next Y	-0.47
EPS next Q	-0.15
EPS this Y	-43.62%
EPS next Y	31.11%
EPS next 5Y	-
EPS past 3/5Y	56.43% 43.17%
Sales past 3/5Y	- -
EPS Y/Y TTM	-43.60%
Sales Y/Y TTM	-
EPS Q/Q	-333.11%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-603.79% -

Insider Own	18.68%
Insider Trans	8.27%
Inst Own	32.30%
Inst Trans	-3.59%
ROA	-33.74%
ROE	-36.19%
ROIC	-41.94%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.29%
SMA50	-8.88%
SMA200	-33.29%
Trades

Shs Outstand	21.04M
Shs Float	17.11M
Short Float	10.06%
Short Ratio	10.55
Short Interest	1.72M
52W High	5.18 -63.03%
52W Low	1.79 6.98%
Volatility	6.95% 4.66%
ATR (14)	0.11
RSI (14)	39.93
Beta	0.43
Rel Volume	0.00
Avg Volume	163.09K
Volume	0

Perf Week	-1.79%
Perf Month	-9.67%
Perf Quarter	-17.81%
Perf Half Y	-18.51%
Perf YTD	-44.65%
Perf Year	-38.03%
Perf 3Y	-21.19%
Perf 5Y	-81.00%
Perf 10Y	-97.32%
Recom	1.00
Target Price	6.00
Prev Close	1.91
Price	1.91
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-25	Initiated	TD Cowen	Buy	$12
Sep-01-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-20	Upgrade	B. Riley FBR	Neutral → Buy	$2
Jan-13-20	Downgrade	B. Riley FBR	Buy → Neutral
Aug-29-19	Initiated	B. Riley FBR	Buy	$7.75
Jul-18-19	Initiated	Oppenheimer	Outperform	$7
Jun-26-19	Initiated	H.C. Wainwright	Buy	$6

Sep-03-26 08:00AM	Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-13-26 08:00AM	Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update (GlobeNewswire)
Aug-04-26 09:00PM	Grace Therapeutics Announces $10 Million Private Placement (GlobeNewswire)
Jul-28-26 07:00AM	Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration (GlobeNewswire)
Jun-18-26 08:00AM	Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update (GlobeNewswire) +7.21%
01:13PM	Loading…
Apr-23-26 01:13PM	Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 (GlobeNewswire) -45.48%
Apr-14-26 08:00AM	Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 (GlobeNewswire) +12.04%
Mar-19-26 08:00AM	Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences (GlobeNewswire)
Feb-25-26 08:00AM	Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 08:00AM	Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Nov-17-25 08:00AM	Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference (GlobeNewswire)
Nov-13-25 08:00AM	Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Nov-11-25 08:30AM	Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting (GlobeNewswire)
Oct-23-25 08:00AM	Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review (GlobeNewswire)
Sep-22-25 08:00AM	Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting (GlobeNewswire)
08:30AM	Loading…
Sep-18-25 08:30AM	Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 (GlobeNewswire)
Sep-04-25 08:00AM	Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-27-25 08:00AM	Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 (GlobeNewswire)
Aug-12-25 08:00AM	Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update (GlobeNewswire)
Jun-25-25 08:00AM	Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 (GlobeNewswire)
Jun-23-25 08:00AM	Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update (GlobeNewswire)
Jun-13-25 08:00AM	Grace Therapeutics to Participate in the 2025 BIO International Conference (GlobeNewswire)
Apr-09-25 08:00AM	Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104 (GlobeNewswire) +9.09%
Mar-11-25 07:00AM	Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Feb-25-25 08:00AM	Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -7.19%
Feb-13-25 08:00AM	Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Feb-11-25 10:26AM	Grace Therapeutics secures $15m for GTx-104 pre-commercial development (Pharmaceutical Technology)
Feb-10-25 12:05PM	Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study (Benzinga) +8.33%
08:05AM	Grace Therapeutics Announces Private Placement Financing of up to $30 Million (GlobeNewswire)
08:01AM	Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH (GlobeNewswire)
08:00AM	Loading…
Jan-07-25 08:00AM	Grace Therapeutics to Participate in Upcoming Investor Events January 2025 (GlobeNewswire)
Dec-04-24 08:00AM	Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference (GlobeNewswire) +20.00%
Nov-13-24 08:00AM	Grace Therapeutics Announces Second Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Oct-30-24 08:00AM	Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024 (GlobeNewswire)
Oct-25-24 08:00AM	Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. (GlobeNewswire)
Sep-25-24 07:30AM	Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 (GlobeNewswire) +19.53%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire) +12.43%
Sep-12-24 08:00AM	Acasti to Present at the Life Sciences Investor Forum (GlobeNewswire) -8.38%
Sep-05-24 10:35AM	Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-09-24 02:52PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q1 2025 (InvestorPlace)
08:00AM	Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update (GlobeNewswire)
Jul-10-24 09:40AM	Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-27-24 04:05PM	Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial (GlobeNewswire)
Jun-21-24 01:53PM	ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024 (InvestorPlace)
08:00AM	Acasti Announces Year-End 2024 Financial Results, Provides Business Update (GlobeNewswire)
Jun-18-24 12:31PM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024 (InvestorPlace)
May-28-24 04:05PM	Acasti Pharma to Attend BIO International Convention 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Feb-12-24 08:00AM	Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +6.53%
07:57AM	Acasti: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Feb-01-24 08:00AM	Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial (GlobeNewswire)
Dec-13-23 08:00AM	Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 (GlobeNewswire)
Nov-13-23 08:20AM	Acasti: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Acasti Announces Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Oct-23-23 08:00AM	Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial (GlobeNewswire)
Oct-04-23 08:00AM	Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH) (GlobeNewswire)
Sep-26-23 08:00AM	Acasti Announces $7.5 Million Private Placement Equity Financing (GlobeNewswire) +35.39%
Sep-06-23 08:00AM	Acasti to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-23-23 03:49AM	TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised) (Zacks)
Aug-22-23 09:19AM	TEVA to Pay $250 Million to Settle Price-Fixing Charges (Zacks)
Aug-11-23 07:10AM	Acasti: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Acasti Announces First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Aug-09-23 04:05PM	Acasti to Present GTX-104 Pharmacokinetic Comparison Data at Neurocritical Care Annual Meeting (GlobeNewswire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-10-23 09:00AM	Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH Patients (PR Newswire) -9.55%
Jul-07-23 08:00AM	Acasti Pharma Announces 1-for-6 Reverse Stock Split (PR Newswire) -12.52%
Jul-05-23 09:00AM	Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023 (PR Newswire) +18.77%
Jun-23-23 07:00AM	Acasti Pharma Reports Fiscal Year 2023 Operational Results (PR Newswire)
Jun-22-23 09:00AM	Acasti Announces Appointment of New Scientific Advisory Board Members (PR Newswire)
May-17-23 09:00AM	Acasti to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
May-10-23 07:41AM	We're Hopeful That Acasti Pharma (NASDAQ:ACST) Will Use Its Cash Wisely (Simply Wall St.)
May-08-23 07:00AM	Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025 (PR Newswire)
Apr-04-23 08:01AM	Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the IND (PR Newswire)
08:00AM	Acasti Announces Appointment of Prashant Kohli as CEO (PR Newswire)
Mar-30-23 08:30AM	Acasti Pharma Inc. Announces the Resignation of a Director (PR Newswire)
06:57AM	When Will Acasti Pharma Inc. (NASDAQ:ACST) Turn A Profit? (Simply Wall St.)
Mar-13-23 08:00AM	Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange (PR Newswire)
Mar-08-23 09:00AM	Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Mar-04-23 08:28AM	We're Hopeful That Acasti Pharma (CVE:ACST) Will Use Its Cash Wisely (Simply Wall St.)
Feb-28-23 01:00PM	Acasti Pharma Recognizes Rare Disease Day (PR Newswire)
09:40AM	Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-15-23 04:02PM	Acasti Pharma Inc. (NASDAQ:ACST) Q3 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-23 07:00AM	Acasti Pharma Reports Third Quarter 2023 Operational Results (GlobeNewswire)
Feb-07-23 09:00AM	Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023 (PR Newswire)
Jan-25-23 09:00AM	Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule (GlobeNewswire)
Jan-24-23 04:15PM	Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE) +5.63%
08:45AM	Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast (Newsfile)
Jan-13-23 09:00AM	Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18 (GlobeNewswire)
Jan-05-23 09:00AM	Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures (GlobeNewswire) +18.32%
Dec-29-22 06:02AM	Acasti Pharma Inc. (NASDAQ:ACST) Q2 2023 Earnings Call Transcript (Insider Monkey)
Dec-28-22 08:00AM	Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Companys Drug Candidate for the Treatment of Ataxia Telangiectasia (GlobeNewswire) +11.09%
Dec-22-22 08:00AM	Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Companys Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN) (GlobeNewswire) +11.99%
Nov-14-22 07:00AM	Acasti Pharma Reports Second Quarter 2023 Operational Results (GlobeNewswire)
Nov-09-22 04:15PM	Acasti Pharma to Present at Q4 Investor Summit (GlobeNewswire)
Nov-07-22 04:15PM	Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 (GlobeNewswire) -6.01%
Sep-30-22 09:00AM	Acasti Announces Court Dismissal of Stockholder Litigation (GlobeNewswire)
Sep-29-22 09:00AM	Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Oct 19 '26	Buy	1.88	4,256	8,001	2,948,610	Oct 21 06:06 PM
Opaleye Management Inc.	10% Owner	Oct 16 '26	Buy	1.89	36,347	68,758	2,944,354	Oct 16 08:42 PM
Opaleye Management Inc.	10% Owner	Oct 15 '26	Buy	1.95	23,485	45,685	2,908,007	Oct 16 08:42 PM
Opaleye Management Inc.	10% Owner	Oct 14 '26	Buy	1.93	11,233	21,735	2,884,522	Oct 16 08:42 PM
Opaleye Management Inc.	10% Owner	Oct 12 '26	Buy	2.02	7,215	14,574	2,873,289	Oct 13 05:45 PM
Opaleye Management Inc.	10% Owner	Oct 09 '26	Buy	2.04	5,340	10,918	2,866,074	Oct 13 05:45 PM
Opaleye Management Inc.	10% Owner	Oct 08 '26	Buy	2.02	2,077	4,190	2,860,734	Oct 13 05:45 PM
Opaleye Management Inc.	10% Owner	Oct 01 '26	Buy	2.04	38,796	78,961	2,836,963	Oct 05 06:46 PM
Opaleye Management Inc.	10% Owner	Oct 02 '26	Buy	2.07	20,000	41,368	2,856,963	Oct 05 06:46 PM
Opaleye Management Inc.	10% Owner	Oct 05 '26	Buy	2.06	1,694	3,490	2,858,657	Oct 05 06:46 PM
Opaleye Management Inc.	10% Owner	Sep 29 '26	Buy	2.09	7,849	16,404	2,798,167	Oct 01 04:30 PM
Opaleye Management Inc.	10% Owner	Sep 21 '26	Buy	2.10	9,771	20,519	2,850,000	Sep 23 06:19 PM
Opaleye Management Inc.	10% Owner	Sep 23 '26	Buy	2.10	5,318	11,168	2,855,318	Sep 23 06:19 PM
Opaleye Management Inc.	10% Owner	Sep 08 '26	Buy	2.10	9,393	19,699	2,769,393	Sep 10 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 09 '26	Buy	2.09	5,836	12,197	2,775,229	Sep 10 04:05 PM
Kohli Prashant	Chief Executive Officer	Sep 09 '26	Buy	2.14	100,000	214,000	121,357	Sep 10 07:30 AM
Opaleye Management Inc.	10% Owner	Aug 14 '26	Buy	2.09	11,608	24,206	2,760,000	Aug 19 07:44 AM

Grace Therapeutics, Inc. engages in the development and commercialization of drug candidates for rare and orphan diseases. It focuses on utilizing proprietary technologies to improve the performance of currently marketed drugs. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Princeton, NJ.

CEO & DirectorMr. Prashant Kohli

VP of Program ManagementMr. Amresh Kumar Ph.D.

ConsultantMs. Carrie D'Andrea

VP of Finance and Principal Financial & Accounting OfficerMr. Robert J. DelAversano CPA

Ph.D.Dr. R. Loch MacDonald M.D.

ACOG Alpha Cognition Inc daily Stock Chart

Peers: AVXL AXSM CGTX ANVS ACAD PRTA INMB ATHE ALZN SUPN

| Held by: AVSC

Index	-
Market Cap	180.97M
Enterprise Value	139.53M
Income	-23.44M
Sales	15.26M
Book/sh	2.43
Cash/sh	1.90
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	71
IPO	Jun 28, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	11.86
P/B	3.42
P/C	4.37
P/FCF	-
EV/EBITDA	-
EV/Sales	9.14
Quick Ratio	8.00
Current Ratio	9.00
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.12
EPS next Y	-0.62
EPS next Q	-0.34
EPS this Y	-12.68%
EPS next Y	53.22%
EPS next 5Y	-
EPS past 3/5Y	35.73% 45.28%
Sales past 3/5Y	- -
EPS Y/Y TTM	31.08%
Sales Y/Y TTM	232.74%
EPS Q/Q	38.34%
Sales Q/Q	267.56%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	-2.01% 36.86%

Insider Own	8.37%
Insider Trans	80.24%
Inst Own	83.06%
Inst Trans	-2.33%
ROA	-42.76%
ROE	-55.25%
ROIC	-44.26%
Gross Margin	89.24%
Oper. Margin	-190.62%
Profit Margin	-153.61%
SMA20	-4.90%
SMA50	-7.13%
SMA200	17.46%
Trades

Shs Outstand	21.77M
Shs Float	14.23M
Short Float	2.27%
Short Ratio	2.58
Short Interest	0.32M
52W High	10.14 -18.05%
52W Low	4.50 84.67%
Volatility	6.24% 5.58%
ATR (14)	0.49
RSI (14)	40.45
Beta	2.34
Rel Volume	0.00
Avg Volume	125.18K
Volume	0

Perf Week	-1.66%
Perf Month	-5.35%
Perf Quarter	5.19%
Perf Half Y	21.31%
Perf YTD	27.85%
Perf Year	20.43%
Perf 3Y	15.86%
Perf 5Y	-69.05%
Perf 10Y	-
Recom	1.20
Target Price	18.00
Prev Close	8.31
Price	8.31
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-26	Initiated	B. Riley Securities	Buy	$21
Jul-10-26	Initiated	Raymond James	Outperform	$20
May-29-26	Initiated	Maxim Group	Buy	$12
Apr-17-26	Initiated	Craig Hallum	Buy	$14
Mar-18-25	Initiated	H.C. Wainwright	Buy	$20

Oct-13-26 08:30AM	Alpha Cognition Announces Publication of U.S. Patent Application Relating to Proprietary Manufacturing Process for ZUNVEYL (Business Wire)
Oct-06-26 08:30AM	Alpha Cognition to Present New ZUNVEYL (Benzgalantamine) Clinical and Real-World Data at ASCP Annual Meeting and NEI Fall Congress (Business Wire)
Oct-02-26 07:06PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-01-26 08:30AM	Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL(Benzgalantamine) Use in Long-Term Care (Business Wire)
Sep-09-26 06:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:00PM	Loading…
Sep-01-26 05:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-17-26 10:43AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26 (Newsfile)
Aug-13-26 04:05PM	Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update (Business Wire)
Aug-03-26 08:30AM	Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update (Business Wire)
Jul-29-26 08:30AM	Alpha Cognition Receives European Patent Covering ZUNVEYL for the Treatment of Mild-to-Moderate Alzheimer's Disease (Business Wire)
Jul-10-26 08:30AM	Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit (Business Wire)
Jun-23-26 08:30AM	Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board (Business Wire)
Jun-09-26 08:00AM	Alpha Cognition Reports Positive Top-Line Results from BEACON Real-World Study of ZUNVEYL in Alzheimers Disease (Business Wire)
May-14-26 04:15PM	Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update (Business Wire) +5.99%
Apr-28-26 04:30PM	Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026 (Business Wire) -5.32%
08:00AM	Loading…
Apr-27-26 08:00AM	Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences (Business Wire) -6.20%
Apr-20-26 05:00PM	Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig (Business Wire)
Apr-15-26 08:00PM	Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-26 04:21PM	Alpha Cognition Inc. (ACOG) Soars 8.6%: Is Further Upside Left in the Stock? (Quartz)
Apr-01-26 04:30PM	Alpha Cognition Receives Issued U.S. Patent for ALPHA-1062 for Treatment of Traumatic Brain Injury (Business Wire) +8.56%
09:51AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425 (Newsfile)
Mar-26-26 04:01PM	Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update (Business Wire)
Mar-13-26 01:46PM	Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026 (Business Wire)
Mar-10-26 08:30AM	Alpha Cognition to Present New Clinical on ZUNVEYL (Benzgalantamine) at Multiple Upcoming Alzheimer's Association International Conferences (Business Wire)
Feb-25-26 08:30AM	Alpha Cognition Announces First Patient Enrolled in BEACON Real-World Effectiveness Study (Business Wire) +5.41%
Feb-18-26 08:30AM	Alpha Cognition Announces Issuance of Additional U.S. Patent Covering ZUNVEYL Dosing Regimens (Business Wire) +11.32%
Jan-07-26 04:30PM	Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution (Business Wire) +5.18%
Dec-05-25 09:40AM	Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year? (Zacks)
Dec-01-25 05:51PM	Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners (Business Wire) -6.15%
Nov-19-25 09:41AM	Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:46AM	Loading…
Nov-14-25 09:46AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q3 2025 (Newsfile)
Nov-13-25 06:40PM	Alpha Cognition Inc. (ACOG) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Alpha Cognition Inc. Reports Third Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Nov-12-25 07:54AM	MDT Q2 Earnings Preview: Cardiovascular Unit Likely to Boost Growth (Zacks)
07:30AM	Alpha Cognition Inc (ACOG) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-30-25 08:30AM	Alpha Cognition (Nasdaq: ACOG) to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, November 13, 2025 (Business Wire) -5.94%
Oct-15-25 09:00AM	Alpha Cognition, Inc. to Present at Spartan Capital Securities' Second Annual Investor Conference (NewMediaWire)
Oct-14-25 04:30PM	Alpha Cognition to Present Clinical Data at Consultant Pharmacy and Neuroscience Education Institute Meetings (Business Wire)
Oct-06-25 08:30AM	Alpha Cognition to Present Clinical Data at ASCP Annual Meeting (Business Wire)
Sep-30-25 11:14PM	Alpha Cognition Inc. Announces Pricing of $35 Million Oversubscribed Public Offering of Common Shares (Business Wire) +13.21%
04:58PM	Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares (Business Wire)
Aug-28-25 01:00PM	Alpha Cognition Inc. (Nasdaq: ACOG) Announces Participation in Key September Investor Conferences (Business Wire)
Aug-15-25 05:10PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q2 2025 (Newsfile) +5.56%
Aug-14-25 06:55PM	Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -19.92%
08:30AM	Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update (Business Wire)
Aug-04-25 08:30AM	Alpha Cognition to Report Second Quarter 2025 Financial Results and Operating Overview (Business Wire)
Jul-29-25 08:30AM	Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL (Benzgalantamine) for Alzheimers Disease (Business Wire)
Jul-08-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Study Data at Alzheimers Association International Conference (Business Wire) -5.07%
Jul-04-25 12:00PM	What Makes Alpha Cognition Inc. (ACOG) a New Strong Buy Stock (Zacks)
Jul-01-25 05:05PM	Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire) +16.20%
09:40AM	Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year? (Zacks)
Jun-16-25 09:55AM	Should You Buy Alpha Cognition Inc. (ACOG) After Golden Cross? (Zacks)
Jun-06-25 04:31PM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
May-19-25 10:25AM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q1 2025 (Newsfile) +15.61%
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +27.02%
08:30AM	Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview (Business Wire)
May-01-25 08:30AM	Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview (Business Wire) +8.33%
Apr-30-25 07:30AM	Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-28-25 08:30AM	Alpha Cognition to Present ZUNVEYL (Benzgalantamine) Clinical Data at 2025 Alzheimer's Association International Conference (Business Wire)
Apr-10-25 08:30AM	Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens (Business Wire)
Apr-01-25 04:27PM	Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 (Newsfile)
Mar-31-25 09:50PM	Alpha Cognition Inc. (ACOG) Q4 2024 Earnings Call Transcript (Seeking Alpha) -8.50%
08:30AM	Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-19-25 04:30PM	Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview (Business Wire)
Mar-18-25 08:30AM	Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer's Disease (Business Wire)
Mar-05-25 08:35AM	Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory (Insider Monkey)
Feb-12-25 08:30AM	Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimers disease (Business Wire)
Jan-30-25 11:05AM	Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG) (Newsfile) -5.06%
Jan-22-25 07:00AM	OTC Markets Group Announces Quarterly Index Performance and Rebalancing (GlobeNewswire)
Jan-14-25 08:30AM	Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL (Business Wire)
Jan-08-25 08:30AM	Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimers Disease, in China (Business Wire)
Jan-06-25 08:30AM	Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimers Long-Term Care Market During Investor Update Call (Business Wire)
Dec-16-24 02:56PM	Alpha Cognition Announces Partial Exercise of Over-allotment Option (Business Wire) -11.62%
Dec-12-24 06:41PM	Alpha Cognition Announces Voluntary Delisting from CSE (Business Wire) -5.57%
Dec-11-24 08:30AM	Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury (Business Wire)
Nov-15-24 05:00PM	Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update (Business Wire) -5.38% +6.15%
Nov-12-24 09:22AM	Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing (Business Wire) -32.14%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Oct 15 '26	Buy	8.43	22,657	190,974	3,245,611	Oct 19 05:34 PM
Opaleye Management Inc.	10% Owner	Oct 16 '26	Buy	8.23	14,283	117,602	3,259,894	Oct 19 05:34 PM
Opaleye Management Inc.	10% Owner	Oct 01 '26	Buy	8.69	19,050	165,634	3,222,954	Oct 02 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 24 '26	Buy	8.57	18,337	157,082	3,190,478	Sep 28 07:57 PM
Opaleye Management Inc.	10% Owner	Sep 25 '26	Buy	8.47	13,426	113,718	3,203,904	Sep 28 07:57 PM
Opaleye Management Inc.	10% Owner	Sep 16 '26	Buy	8.51	80,170	682,591	3,172,141	Sep 16 05:57 PM
Opaleye Management Inc.	10% Owner	Sep 14 '26	Buy	8.70	40,373	351,084	3,088,596	Sep 16 05:57 PM
Opaleye Management Inc.	10% Owner	Sep 15 '26	Buy	8.54	3,375	28,831	3,091,971	Sep 16 05:57 PM
Wills Robert James	Director	Aug 21 '26	Buy	9.62	10,000	96,200	32,241	Aug 24 02:52 PM
Opaleye Management Inc.	10% Owner	Aug 03 '26	Buy	8.00	50,000	400,000	3,048,223	Aug 04 04:50 PM
Opaleye Management Inc.	10% Owner	Jul 31 '26	Buy	7.92	2,900	22,976	2,998,223	Aug 04 04:50 PM
Opaleye Management Inc.	10% Owner	Jul 24 '26	Buy	7.90	130	1,027	2,995,323	Jul 28 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 22 '26	Buy	7.83	150,237	1,176,912	2,945,344	Jul 24 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 23 '26	Buy	7.80	49,849	388,588	2,995,193	Jul 24 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 26 '26	Buy	6.40	152,336	975,209	2,805,107	Jun 29 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 25 '26	Buy	6.50	197	1,280	2,652,771	Jun 29 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 15 '26	Buy	5.99	4,550	27,253	2,652,574	Jun 15 08:10 PM
Opaleye Management Inc.	10% Owner	Jun 11 '26	Buy	5.91	2,862	16,901	2,647,751	Jun 15 08:10 PM
Opaleye Management Inc.	10% Owner	Jun 12 '26	Buy	5.93	273	1,619	2,648,024	Jun 15 08:10 PM
Opaleye Management Inc.	10% Owner	Jun 09 '26	Buy	5.98	24,856	148,534	2,639,017	Jun 11 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 10 '26	Buy	5.99	5,872	35,157	2,644,889	Jun 11 04:05 PM
Opaleye Management Inc.	10% Owner	Jun 05 '26	Buy	5.83	10,054	58,596	2,614,161	Jun 09 04:05 PM
Opaleye Management Inc.	10% Owner	May 29 '26	Buy	5.90	70,577	416,397	2,604,107	May 29 07:21 PM
Opaleye Management Inc.	10% Owner	May 28 '26	Buy	5.83	2,000	11,664	2,533,530	May 29 07:21 PM
Opaleye Management Inc.	10% Owner	May 27 '26	Buy	5.73	1,161	6,653	2,531,530	May 29 07:21 PM
Opaleye Management Inc.	10% Owner	May 21 '26	Buy	5.70	15,945	90,886	2,530,369	May 22 04:05 PM
Opaleye Management Inc.	10% Owner	May 20 '26	Buy	5.89	8,431	49,659	2,514,424	May 22 04:05 PM
D'Angelo Lauren	Chief Operating Officer	May 19 '26	Buy	5.76	3,500	20,160	140,695	May 19 05:02 PM
Opaleye Management Inc.	10% Owner	May 18 '26	Buy	5.69	17,395	99,023	2,505,993	May 19 04:05 PM
Opaleye Management Inc.	10% Owner	May 15 '26	Buy	5.83	16,648	96,986	2,488,598	May 19 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 27 '26	Buy	5.08	10,000	50,792	2,470,000	Mar 31 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 30 '26	Buy	4.99	1,850	9,227	2,471,850	Mar 31 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 25 '26	Buy	5.43	8,581	46,579	2,452,681	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 26 '26	Buy	5.28	7,319	38,675	2,460,000	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 24 '26	Buy	5.59	4,182	23,377	2,444,100	Mar 26 06:57 PM
Opaleye Management Inc.	10% Owner	Mar 18 '26	Buy	5.75	2,481	14,263	2,437,824	Mar 20 04:54 PM
Opaleye Management Inc.	10% Owner	Mar 19 '26	Buy	5.71	2,094	11,950	2,439,918	Mar 20 04:54 PM
Opaleye Management Inc.	10% Owner	Mar 16 '26	Buy	5.78	1,331	7,696	2,435,343	Mar 18 06:55 PM
Opaleye Management Inc.	10% Owner	Mar 13 '26	Buy	5.75	7,358	42,286	2,434,012	Mar 13 06:43 PM
Opaleye Management Inc.	10% Owner	Mar 12 '26	Buy	5.85	5,708	33,416	2,426,654	Mar 13 06:43 PM
Opaleye Management Inc.	10% Owner	Mar 09 '26	Buy	5.85	2,179	12,742	2,420,946	Mar 10 06:47 PM
Opaleye Management Inc.	10% Owner	Mar 06 '26	Buy	5.80	1,900	11,018	2,418,767	Mar 10 06:47 PM
Opaleye Management Inc.	10% Owner	Mar 05 '26	Buy	5.80	47,023	272,621	2,416,867	Mar 06 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 04 '26	Buy	5.81	19,795	115,001	2,374,844	Mar 06 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '26	Buy	5.75	51,411	295,624	2,355,049	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 02 '26	Buy	5.80	20,000	116,000	2,308,638	Mar 04 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 27 '26	Buy	5.99	3,638	21,797	2,288,638	Mar 02 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 26 '26	Buy	5.99	590	3,531	2,285,000	Mar 02 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 23 '26	Buy	5.89	100,000	589,230	2,230,819	Feb 24 05:52 PM
Opaleye Management Inc.	10% Owner	Feb 24 '26	Buy	5.80	58,591	339,851	2,284,410	Feb 24 05:52 PM
Opaleye Management Inc.	10% Owner	Feb 20 '26	Buy	5.84	12,819	74,877	2,135,000	Feb 24 05:52 PM

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal ("ALPHA-1062IN") formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.

CEO & DirectorMr. Michael E. McFadden B.B.A.

LL.B.Mr. Kenneth Anthony Cawkell B.A.

VP of Finance & Accounting and Interim CFOMr. Henry H. Du CPA

Chief Operating OfficerMs. Lauren D'Angelo M.B.A.

Ph.D.Dr. Denis G. Kay M.Sc.

SLGL Sol-Gel Technologies Ltd daily Stock Chart

Peers: PVLA VRCA PTHS ARQT ACRS DERM EVMN BFRI KRYS DRMA

| Held by: IZRL QQQS

Index	-
Market Cap	220.63M
Enterprise Value	173.47M
Income	-16.34M
Sales	1.79M
Book/sh	14.69
Cash/sh	14.64
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	28
IPO	Feb 01, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	123.26
P/B	4.59
P/C	4.60
P/FCF	-
EV/EBITDA	-
EV/Sales	96.91
Quick Ratio	10.37
Current Ratio	10.37
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-5.64
EPS next Y	-9.06
EPS next Q	-2.07
EPS this Y	-253.14%
EPS next Y	-16.88%
EPS next 5Y	-
EPS past 3/5Y	30.15% 29.88%
Sales past 3/5Y	70.92% 17.19%
EPS Y/Y TTM	-361.11%
Sales Y/Y TTM	-92.50%
EPS Q/Q	-127.01%
Sales Q/Q	-96.58%
Earnings	Aug 20 BMO
EPS/Sales Surpr.	52.12% 688.00%

Insider Own	59.73%
Insider Trans	3.44%
Inst Own	45.92%
Inst Trans	9.47%
ROA	-35.11%
ROE	-40.85%
ROIC	-33.79%
Gross Margin	-
Oper. Margin	-989.97%
Profit Margin	-910.14%
SMA20	-3.97%
SMA50	-4.48%
SMA200	-8.65%
Trades

Shs Outstand	3.27M
Shs Float	1.32M
Short Float	11.05%
Short Ratio	2.70
Short Interest	0.15M
52W High	97.97 -31.21%
52W Low	28.81 133.91%
Volatility	6.86% 6.57%
ATR (14)	4.29
RSI (14)	47.02
Beta	1.26
Rel Volume	0.00
Avg Volume	53.97K
Volume	0

Perf Week	-1.91%
Perf Month	12.86%
Perf Quarter	-17.78%
Perf Half Y	-6.79%
Perf YTD	59.92%
Perf Year	72.35%
Perf 3Y	343.36%
Perf 5Y	-25.63%
Perf 10Y	-
Recom	1.00
Target Price	152.50
Prev Close	67.39
Price	67.39
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-26	Initiated	Cantor Fitzgerald	Overweight
Jun-24-26	Initiated	Mizuho	Outperform	$285
May-29-26	Initiated	TD Cowen	Buy
Aug-19-24	Downgrade	Raymond James	Strong Buy → Outperform	$6 → $4
Oct-21-22	Resumed	Jefferies	Hold	$5.50
Dec-31-19	Reiterated	JMP Securities	Mkt Outperform	$20 → $33
Dec-31-19	Reiterated	H.C. Wainwright	Buy	$23 → $26

Sep-30-26 09:14AM	Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026 (GlobeNewswire)
Sep-17-26 08:30AM	Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome (GlobeNewswire)
Aug-20-26 08:30AM	Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-22-26 10:34AM	What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin's Rare-Obesity Opportunity (FinanceWire) -6.06%
May-28-26 08:00AM	Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
09:38PM	Loading…
Mar-23-26 09:38PM	Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering (GlobeNewswire) -9.28% +20.86%
Mar-19-26 08:53AM	Sol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025 (GlobeNewswire) +8.46%
Mar-12-26 11:55AM	This Under-the-Radar Stock Has Surged 1,300% Over the Past Year (Barchart) -9.52%
Dec-17-25 07:00AM	Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease (GlobeNewswire)
Nov-20-25 07:30AM	Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Sep-04-25 07:00AM	Sol-Gel Announces Health Canada Approval of EPSOLAY (GlobeNewswire) +19.66%
Aug-15-25 07:00AM	Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-23-25 07:15AM	Sol-Gel Reports First Quarter 2025 Results (GlobeNewswire)
May-01-25 07:00AM	Sol-Gel Announces Reverse Share Split (GlobeNewswire)
Apr-17-25 08:40AM	Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. (GlobeNewswire) +14.58%
12:00PM	Loading…
Nov-20-24 12:00PM	SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know (Zacks)
07:00AM	Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement (GlobeNewswire)
Nov-15-24 08:10AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Sep-17-24 09:55AM	SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-27-24 12:00PM	All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy (Zacks) +10.22%
Aug-17-24 11:27AM	UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-16-24 08:10AM	Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Jul-25-24 07:00AM	Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa (GlobeNewswire) -32.85%
Jul-15-24 07:00AM	Sol-Gel Technologies Announces Management Realignment (GlobeNewswire) -8.13%
May-28-24 07:00AM	Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice (GlobeNewswire)
May-20-24 01:53PM	SLGL Stock Earnings: Sol-Gel Technologies Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -6.00%
08:10AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:00AM	Loading…
May-16-24 06:00AM	Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO in the Mainland of China, Hong Kong, Macau, Taiwan and Israel (GlobeNewswire) +5.65%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-13-24 07:00AM	Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments (GlobeNewswire)
Nov-30-23 07:00AM	Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study (GlobeNewswire)
Nov-28-23 08:06AM	Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 (GlobeNewswire)
Nov-09-23 07:00AM	Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-23 06:43AM	Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies (Zacks)
Oct-30-23 10:05AM	3 Generic Drug Stocks to Watch Amid Improving Market Prospects (Zacks)
Aug-30-23 08:00AM	Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 08:15AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-21-23 06:04AM	Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Top Key Executive Moshe Arkin is the most upbeat insider, and their holdings increased by 15% last week (Simply Wall St.) +6.20%
Jun-06-23 07:30AM	Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada (Business Wire)
Jun-02-23 06:09AM	Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) are in the red if they invested five years ago (Simply Wall St.)
May-12-23 08:25AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-22-23 08:19AM	Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Invest In Growth (Simply Wall St.)
Mar-22-23 05:43AM	Load Up, Says Raymond James About These 3 Strong Buy Stocks (TipRanks) +14.69%
Mar-20-23 07:00AM	Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-12-23 08:23AM	Sol-Gel Technologies Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-10-23 08:15AM	Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments (GlobeNewswire)
Feb-27-23 06:02AM	Could The Market Be Wrong About Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Its Attractive Financial Prospects? (Simply Wall St.) +6.02%
Feb-23-23 02:32PM	The Top 7 Penny Stocks to Invest in for the Long-Term (InvestorPlace) -6.35%
Jan-27-23 07:29AM	Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings (GlobeNewswire)
07:00AM	Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million (GlobeNewswire)
Dec-08-22 06:16AM	Zacks Industry Outlook Highlights Dr. Reddy's, Amphastar Pharmaceuticals and Sol-Gel Technologies (Zacks)
Dec-07-22 10:52AM	3 Generic Drug Stocks to Watch Amid Inflation Pressures (Zacks)
Nov-10-22 04:00AM	Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-03-22 03:03PM	Sol-Gel Technologies (NASDAQ:SLGL) investors are sitting on a loss of 45% if they invested a year ago (Simply Wall St.)
Oct-03-22 08:00AM	Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development (GlobeNewswire)
Sep-19-22 01:00PM	Are Strong Financial Prospects The Force That Is Driving The Momentum In Sol-Gel Technologies Ltd.'s NASDAQ:SLGL) Stock? (Simply Wall St.)
Sep-12-22 04:30AM	Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel (Zacks)
Sep-09-22 12:13PM	3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure (Zacks)
Aug-04-22 06:00AM	Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.64%
Jun-01-22 08:00AM	Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference (GlobeNewswire)
May-27-22 11:45AM	Investors in Sol-Gel Technologies (NASDAQ:SLGL) have unfortunately lost 43% over the last year (Simply Wall St.) +6.53%
May-17-22 07:00AM	Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-13-22 07:00AM	Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +6.00%
Apr-25-22 07:00AM	Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY® (GlobeNewswire) -7.61%
Apr-14-22 08:30AM	Sol-Gel Technologies Announces the Commercial Availability of TWYNEO® (GlobeNewswire) +9.94%
Apr-12-22 11:26AM	Are Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness? (Simply Wall St.)
Mar-30-22 07:00AM	Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments (GlobeNewswire)
Mar-25-22 11:00AM	Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA (GlobeNewswire)
Dec-22-21 04:05PM	Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference (GlobeNewswire)
Dec-21-21 07:00AM	Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY® (GlobeNewswire)
Nov-30-21 08:27AM	Shareholders in Sol-Gel Technologies (NASDAQ:SLGL) have lost 23%, as stock drops 12% this past week (Simply Wall St.) +9.10%
Nov-11-21 07:00AM	Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire)
Nov-09-21 07:05AM	Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-21 07:30AM	Sol-Gel Technologies Announces Sale of Generic Dermatology Portfolio to Partner Padagis for $21 Million (GlobeNewswire)
Oct-01-21 12:14PM	Will Sol-Gel Technologies (NASDAQ:SLGL) Spend Its Cash Wisely? (Simply Wall St.)
Sep-22-21 07:30AM	Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference (GlobeNewswire) -6.09%
Sep-09-21 08:30AM	Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-17-21 01:30PM	What Is The Ownership Structure Like For Sol-Gel Technologies Ltd. (NASDAQ:SLGL)? (Simply Wall St.)
Aug-04-21 07:05AM	Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments (GlobeNewswire) -5.67%
Jul-27-21 10:26AM	Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris (Benzinga)
09:15AM	Sol-Gel Technologies Announces FDA Approval of TWYNEO® (GlobeNewswire)
Jul-20-21 07:05AM	Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021 (GlobeNewswire)
Jun-28-21 05:10AM	Sol-Gel Announces Pipeline Update and Future Development Plans (GlobeNewswire) -6.79%
05:00AM	Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States (Business Wire)
May-27-21 07:00AM	Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference (GlobeNewswire)
May-18-21 09:27AM	Does Sol-Gel Technologies' (NASDAQ:SLGL) Share Price Gain of 23% Match Its Business Performance? (Simply Wall St.)
May-13-21 07:05AM	Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update (GlobeNewswire) +15.19%
Apr-28-21 08:41PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sol-Gel Technologies Ltd. - SLGL (Newsfile) -6.33%
Apr-27-21 02:20PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Sol-Gel Technologies Ltd. (SLGL) Investigation (ACCESSWIRE) -12.66%
10:02AM	Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY® (GlobeNewswire)
Mar-19-21 06:56AM	Sol-Gel Technologies (NASDAQ:SLGL) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-10-21 10:29AM	Raymond James: These 3 Stocks Are Poised to Surge by at Least 50% (TipRanks) +10.79%
Mar-04-21 07:05AM	Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update (GlobeNewswire) -8.42%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Sep 10 '26	Buy	66.80	1,631	108,943	538,507	Sep 14 05:23 PM
Opaleye Management Inc.	10% Owner	Sep 11 '26	Buy	65.94	1,493	98,456	540,000	Sep 14 05:23 PM
Opaleye Management Inc.	10% Owner	Sep 08 '26	Buy	68.82	3,861	265,703	533,779	Sep 09 07:18 PM
Opaleye Management Inc.	10% Owner	Sep 09 '26	Buy	68.70	3,097	212,779	536,876	Sep 09 07:18 PM
Opaleye Management Inc.	10% Owner	Sep 04 '26	Buy	69.14	3,018	208,677	529,918	Sep 09 07:18 PM
Opaleye Management Inc.	10% Owner	Sep 02 '26	Buy	68.95	900	62,054	526,900	Sep 03 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 01 '26	Buy	69.52	783	54,434	526,000	Sep 03 04:05 PM
Opaleye Management Inc.	10% Owner	Aug 28 '26	Buy	69.32	35,113	2,434,156	520,000	Aug 31 06:24 PM
Opaleye Management Inc.	10% Owner	Aug 31 '26	Buy	68.27	5,217	356,170	525,217	Aug 31 06:24 PM
Opaleye Management Inc.	10% Owner	Aug 12 '26	Buy	71.50	951	67,996	494,887	Aug 14 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 14 '26	Buy	73.43	920	67,556	493,936	Jul 15 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 13 '26	Buy	73.89	775	57,263	493,016	Jul 15 04:05 PM
Opaleye Management Inc.	10% Owner	Jul 08 '26	Buy	73.69	300	22,107	492,012	Jul 10 04:41 PM
Opaleye Management Inc.	10% Owner	Jul 10 '26	Buy	73.95	229	16,935	492,241	Jul 10 04:41 PM
Opaleye Management Inc.	10% Owner	Jul 02 '26	Buy	71.97	1,400	100,759	491,712	Jul 02 06:11 PM
Opaleye Management Inc.	10% Owner	Jul 01 '26	Buy	71.99	312	22,461	490,312	Jul 02 06:11 PM
Opaleye Management Inc.	10% Owner	May 20 '26	Buy	64.43	1,563	100,712	490,000	May 22 04:05 PM
Opaleye Management Inc.	10% Owner	May 13 '26	Buy	66.87	1,937	129,527	488,437	May 14 04:05 PM
Opaleye Management Inc.	10% Owner	May 12 '26	Buy	67.98	1,500	101,975	486,500	May 14 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 24 '26	Buy	72.00	39,665	2,855,880	485,000	Mar 24 04:05 PM
Yosef Itzik	Officer	Mar 11 '26	Proposed Sale	88.70	142	12,595		Mar 12 07:11 AM
Yosef Itzik	Officer	Feb 25 '26	Proposed Sale	87.63	1,556	136,352		Feb 26 06:21 AM
Yosef Itzik	Officer	Feb 23 '26	Proposed Sale	83.98	1,170	98,257		Feb 24 07:41 AM
Opaleye Management Inc.	10% Owner	Feb 13 '26	Buy	63.00	291	18,333	450,335	Feb 18 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 02 '26	Buy	58.00	100	5,800	450,944	Feb 04 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 27 '26	Buy	57.05	100	5,705	449,944	Jan 29 04:16 PM
Opaleye Management Inc.	10% Owner	Jan 22 '26	Buy	56.57	2,173	122,922	448,693	Jan 23 05:42 PM
Opaleye Management Inc.	10% Owner	Jan 23 '26	Buy	55.98	1,151	64,434	449,844	Jan 23 05:42 PM
Yosef Itzik	Officer	Jan 14 '26	Proposed Sale	62.94	713	44,876		Jan 15 06:54 AM
Opaleye Management Inc.	10% Owner	Jan 02 '26	Buy	41.92	2,394	100,348	447,133	Jan 06 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 05 '26	Buy	42.98	198	8,510	447,331	Jan 06 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 30 '25	Buy	41.99	35,169	1,476,627	421,242	Dec 31 05:45 PM
Opaleye Management Inc.	10% Owner	Dec 31 '25	Buy	41.99	22,497	944,744	443,739	Dec 31 05:45 PM
Opaleye Management Inc.	10% Owner	Dec 29 '25	Buy	41.85	8,638	361,534	386,073	Dec 31 05:45 PM
Opaleye Management Inc.	10% Owner	Dec 26 '25	Buy	41.68	1,626	67,765	377,435	Dec 29 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 22 '25	Buy	41.15	1,019	41,936	375,549	Dec 29 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 23 '25	Buy	41.66	260	10,832	375,809	Dec 29 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 17 '25	Buy	40.37	2,735	110,412	374,530	Dec 19 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 12 '25	Buy	40.00	87	3,480	371,795	Dec 16 04:05 PM
Opaleye Management Inc.	10% Owner	Dec 05 '25	Buy	39.50	444	17,537	371,408	Dec 09 04:12 PM
Opaleye Management Inc.	10% Owner	Dec 08 '25	Buy	39.77	300	11,932	371,708	Dec 09 04:12 PM
Opaleye Management Inc.	10% Owner	Dec 01 '25	Buy	37.37	4,340	162,167	368,440	Dec 03 05:39 PM
Opaleye Management Inc.	10% Owner	Dec 03 '25	Buy	37.81	2,524	95,443	370,964	Dec 03 05:39 PM
Opaleye Management Inc.	10% Owner	Nov 26 '25	Buy	40.00	943	37,720	364,100	Nov 26 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 24 '25	Buy	35.50	6	213	363,157	Nov 26 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 20 '25	Buy	35.83	5,784	207,244	363,151	Nov 21 04:05 PM

Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.

Chief Financial OfficerMr. Eyal Ben-Or

Chief Operating OfficerDr. Itzik Yosef

Chief Business OfficerMr. Michael Glezin

CEO & Executive ChairmanMr. Moshe Arkin

ETON Eton Pharmaceuticals Inc daily Stock Chart

Peers: XERS NBIX ANIP HROW ZVRA TVTX HRMY ASND RYTM SPRB

| Held by: VTI IWM VXF IWO FYC VTWO XPH SCHA FYX IWC

Index	RUT
Market Cap	1.45B
Enterprise Value	1.46B
Income	12.69M
Sales	105.59M
Book/sh	1.65
Cash/sh	0.94
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	44
IPO	Nov 13, 2018

P/E	134.58
Forward P/E	24.42
PEG	0.23
P/S	13.78
P/B	30.91
P/C	54.21
P/FCF	98.77
EV/EBITDA	69.23
EV/Sales	13.80
Quick Ratio	1.30
Current Ratio	1.52
Debt/Eq	0.63
LT Debt/Eq	0.43
Option/Short	Yes / Yes

EPS (ttm)	0.38
EPS next Y	2.08
EPS next Q	0.31
EPS this Y	210.54%
EPS next Y	91.79%
EPS next 5Y	107.84%
EPS past 3/5Y	21.89% 33.66%
Sales past 3/5Y	55.53% 359.57%
EPS Y/Y TTM	399.54%
Sales Y/Y TTM	81.49%
EPS Q/Q	467.43%
Sales Q/Q	98.59%
Earnings	Aug 13 AMC
EPS/Sales Surpr.	84.40% 38.67%

Insider Own	4.93%
Insider Trans	-30.01%
Inst Own	69.97%
Inst Trans	10.87%
ROA	11.67%
ROE	35.97%
ROIC	19.01%
Gross Margin	57.87%
Oper. Margin	15.63%
Profit Margin	12.02%
SMA20	-4.43%
SMA50	-10.63%
SMA200	46.22%
Trades

Shs Outstand	28.29M
Shs Float	27.17M
Short Float	6.75%
Short Ratio	3.14
Short Interest	1.83M
52W High	66.37 -23.31%
52W Low	14.27 256.69%
Volatility	4.68% 6.24%
ATR (14)	2.77
RSI (14)	42.35
Beta	0.89
Rel Volume	0.07
Avg Volume	583.32K
Volume	1,964

Perf Week	1.17%
Perf Month	-14.44%
Perf Quarter	20.30%
Perf Half Y	121.11%
Perf YTD	201.01%
Perf Year	174.54%
Perf 3Y	1215.25%
Perf 5Y	823.77%
Perf 10Y	-
Recom	1.00
Target Price	71.50
Prev Close	50.02
Price	50.90
Change %	1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-26	Initiated	Canaccord Genuity	Buy	$60
Jan-23-25	Reiterated	H.C. Wainwright	Buy	$17 → $33
Jan-10-25	Initiated	B. Riley Securities	Buy	$21
Jan-06-25	Reiterated	H.C. Wainwright	Buy	$15 → $17
Sep-04-24	Resumed	H.C. Wainwright	Buy	$9
May-06-24	Initiated	Craig Hallum	Buy	$8
Oct-14-21	Resumed	B. Riley Securities	Buy	$10
Jan-04-21	Reiterated	H.C. Wainwright	Buy	$20 → $15
Sep-20-19	Initiated	B. Riley FBR	Buy	$13.50
Jun-10-19	Initiated	H.C. Wainwright	Buy	$15

Oct-14-26 06:50AM	Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT (diazepam) Buccal Film (GlobeNewswire)
Sep-28-26 06:50AM	Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO (miltefosine) Capsules (GlobeNewswire)
Aug-27-26 06:50AM	Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-21-26 12:14PM	Three Biotech Stocks Stick Out With Their Stellar Charts (Investor's Business Daily) +5.94%
Aug-14-26 01:30PM	This Analyst Believes Eton Pharmas Raised Guidance Is Conservative ETON Stock Heads For Best Ever Day (Stocktwits) +44.26%
01:02AM	Loading…
01:02AM	Eton Pharmaceuticals Inc (ETON) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
Aug-13-26 04:05PM	Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-12-26 09:23AM	Earnings To Watch: Eton Pharmaceuticals Inc (ETON) Q2 2026 -- GF Value Sees 27% Downside (GuruFocus.com)
Aug-05-26 06:50AM	Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 (GlobeNewswire)
Aug-03-26 06:50AM	Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 (GlobeNewswire)
Jul-29-26 06:50AM	Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI (hydrocortisone) Oral Solution (GlobeNewswire)
Jul-28-26 12:46PM	ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock? (Stocktwits) +10.28%
Jul-17-26 09:41AM	Apple upgraded, Brinker initiated: Wall Street's top analyst calls (The Fly) +13.79%
May-19-26 04:30PM	Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) (GlobeNewswire)
May-15-26 01:02AM	Eton Pharmaceuticals Inc (ETON) Q1 2026 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
04:05PM	Loading…
May-14-26 04:05PM	Eton Pharmaceuticals Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-12-26 04:30PM	Eton Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-04-26 04:30PM	Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 (GlobeNewswire)
May-01-26 06:50AM	Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution (GlobeNewswire) +19.82%
Apr-27-26 06:50AM	Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700 (GlobeNewswire)
Apr-16-26 06:50AM	Eton Pharmaceuticals Announces CFO Succession Plan (GlobeNewswire) -9.42%
Mar-19-26 11:01PM	Eton Pharmaceuticals Inc (ETON) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +9.20% +7.46%
04:05PM	Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-03-26 04:30PM	Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 (GlobeNewswire)
Mar-02-26 07:27AM	Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL (propranolol hydrochloride) Oral Solution (GlobeNewswire) +6.83%
Feb-25-26 01:47PM	Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA (desmopressin acetate) Oral Solution (GlobeNewswire)
Feb-20-26 06:50AM	Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th (GlobeNewswire)
Feb-02-26 06:50AM	Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate (GlobeNewswire)
Dec-04-25 03:28PM	Implied Volatility Surging for Eton Pharmaceuticals Stock Options (Zacks)
Nov-24-25 04:30PM	Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th (GlobeNewswire)
04:30PM	Loading…
Nov-12-25 04:30PM	Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th (GlobeNewswire)
Nov-06-25 05:35PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -11.70%
04:05PM	Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-05-25 07:49AM	Eton Pharmaceuticals Inc (ETON) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-23-25 04:30PM	Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 (GlobeNewswire)
Sep-22-25 12:57PM	Implied Volatility Surging for Eton Pharmaceuticals Stock Options (Zacks)
Aug-20-25 06:50AM	Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-07-25 06:10PM	Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +12.32%
04:05PM	Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 10:00AM	Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-28-25 07:00AM	Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (GlobeNewswire)
Jul-11-25 10:05AM	Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer (GlobeNewswire) -6.88%
Jul-08-25 06:50AM	Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) (GlobeNewswire) +9.80%
Jun-27-25 06:50AM	Eton Pharmaceuticals Announces Addition to Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-02-25 12:00PM	Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why (Zacks)
08:50AM	Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-29-25 07:12AM	FDA approves Etons application for hydrocortisone oral solution (Pharmaceutical Technology) -5.78%
May-28-25 11:49PM	Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency (Insider Monkey)
05:28PM	Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI (hydrocortisone) Oral Solution (GlobeNewswire)
May-14-25 04:30PM	Eton Pharmaceuticals to Participate at Upcoming Investor Conferences (GlobeNewswire) +15.07%
09:19AM	Q1 2025 Eton Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	Eton Pharmaceuticals Inc (ETON) Q1 2025 Earnings Call Highlights: Revenue Soars 117% Amid ... (GuruFocus.com)
May-13-25 05:15PM	Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates (Zacks)
04:01PM	Eton Pharmaceuticals Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-12-25 09:32AM	Eton Pharmaceuticals Inc (ETON) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:45PM	TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-07-25 10:00AM	Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline (Zacks)
May-01-25 04:30PM	Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 (GlobeNewswire)
10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:50AM	Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) (GlobeNewswire)
Apr-01-25 07:00AM	Eton Pharmaceuticals Out-Licenses International Rights to Increlex (GlobeNewswire)
Mar-21-25 10:56PM	Eton Pharmaceuticals Inc (ETON) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-18-25 08:00AM	Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
06:50AM	Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results (GlobeNewswire)
Mar-14-25 06:50AM	Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 (GlobeNewswire) +6.71%
Mar-04-25 06:50AM	Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 (GlobeNewswire)
Mar-03-25 06:50AM	Eton Pharmaceuticals Announces Commercial Launch of Galzin (zinc acetate) Capsules (GlobeNewswire)
Feb-10-25 07:11AM	Eton secures US patent for diabetes insipidus treatment (Pharmaceutical Technology)
Feb-07-25 06:50AM	Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600 (GlobeNewswire)
Feb-06-25 06:50AM	Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400 (GlobeNewswire)
Jan-25-25 09:15AM	Eton Pharmaceuticals price target raised to $23 from $18 at Craig-Hallum (TipRanks)
Jan-24-25 04:17AM	Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength? (Zacks)
Jan-15-25 01:46PM	Eton Pharmaceuticals, Inc. (ETON): Analysts Recommend This 52-Week High Stocks Now (Insider Monkey) +6.56%
Jan-03-25 06:50AM	Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin (GlobeNewswire) -9.15%
Dec-20-24 06:50AM	Eton Pharmaceuticals Closes Acquisition of Increlex (mecasermin injection) (GlobeNewswire)
Dec-17-24 06:50AM	Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial (GlobeNewswire)
Dec-03-24 06:50AM	Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer (GlobeNewswire) -5.14%
Nov-26-24 09:48AM	Eton acquires US rights to neonatal diabetes treatment from AMMTeK (Pharmaceutical Technology)
06:55AM	Eton Pharmaceuticals acquires U.S. rights to Amglidia from AMMTeK (TipRanks)
Nov-25-24 06:50AM	Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) (GlobeNewswire) +7.12%
Nov-13-24 07:09AM	Q3 2024 Eton Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +15.59%
02:18AM	Eton Pharmaceuticals Inc (ETON) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-12-24 04:01PM	Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results (GlobeNewswire) -5.56%
Nov-11-24 07:18AM	What To Expect From Eton Pharmaceuticals Inc (ETON) Q3 2024 Earnings (GuruFocus.com) +10.59%
Nov-07-24 07:00AM	Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution) (GlobeNewswire)
Nov-06-24 04:30PM	Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-29-24 09:30AM	Eton Pharmaceuticals price target raised to $15 from $10 at Craig-Hallum (TipRanks)
Oct-28-24 11:01AM	Opaleye Management Inc. Reduces Stake in Eton Pharmaceuticals Inc. (GuruFocus.com)
Oct-17-24 04:15PM	SWK Holdings Provides Portfolio Update (ACCESSWIRE)
Oct-09-24 01:02AM	Opaleye Management Inc. Bolsters Portfolio with Strategic Acquisition of Eton Pharmaceuticals Shares (GuruFocus.com)
Oct-03-24 06:30AM	Eton Pharmaceuticals, Inc to Acquire Increlex (mecasermin injection) from Ipsen (GlobeNewswire) +16.33%
Sep-13-24 02:22AM	Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc. (GuruFocus.com) +6.85%
Aug-22-24 04:30PM	Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +6.82%
Aug-08-24 09:59PM	ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
04:01PM	Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 05:30PM	Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jul-17-24 04:15PM	SWK Holdings Highlights Recent Achievements and Provides Portfolio Update (ACCESSWIRE)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krempa David	Chief Business Officer	Oct 06 '26	Sale	55.07	4,166	229,406	43,381	Oct 06 04:49 PM
Krempa David	Officer	Oct 06 '26	Proposed Sale	55.07	4,166	229,406		Oct 06 04:05 PM
MAIER PAUL V	Director	Aug 28 '26	Option Exercise	3.78	50,000	189,000	109,745	Aug 28 04:51 PM
MAIER PAUL V	Director	Aug 28 '26	Sale	59.07	50,000	2,953,572	59,745	Aug 28 04:51 PM
MAIER PAUL V	Director	Aug 28 '26	Proposed Sale	59.07	50,000	2,953,530		Aug 28 04:41 PM
Krempa David	Chief Business Officer	Aug 24 '26	Option Exercise	7.31	25,000	182,750	62,025	Aug 24 05:19 PM
Krempa David	Chief Business Officer	Aug 24 '26	Sale	65.07	25,000	1,626,750	37,025	Aug 24 05:19 PM
Krempa David	Officer	Aug 24 '26	Proposed Sale	65.07	25,000	1,626,750		Aug 24 04:19 PM
BRYNJELSEN SEAN	President & CEO	Aug 20 '26	Sale	60.70	91,022	5,525,301	961,194	Aug 20 06:26 PM
BRYNJELSEN SEAN	President & CEO	Aug 19 '26	Sale	62.65	8,978	562,472	1,052,216	Aug 20 06:26 PM
BRYNJELSEN SEAN	Director	Aug 19 '26	Proposed Sale	63.43	100,000	6,343,000		Aug 19 10:49 AM
Opaleye Management Inc.	10% Owner	Jul 14 '26	Sale	37.54	28,315	1,063,033	40,000	Jul 16 05:14 PM
BRYNJELSEN SEAN	President & CEO	Jul 14 '26	Option Exercise	1.37	200,000	274,000	1,061,194	Jul 14 05:28 PM
Opaleye Management Inc.	10% Owner	Jul 02 '26	Sale	37.39	90,000	3,364,659	60,000	Jul 07 06:29 PM
Opaleye Management Inc.	10% Owner	Jul 07 '26	Sale	38.37	26,685	1,023,978	53,315	Jul 07 06:29 PM
Opaleye Management Inc.	10% Owner	Jul 06 '26	Sale	38.00	10,000	380,000	2,700,000	Jul 07 06:29 PM
Gruber James R.	Officer	Jun 26 '26	Proposed Sale	35.70	251,818	8,990,000		Jun 26 04:14 PM
Gruber James R.	Officer	Jun 25 '26	Proposed Sale	35.01	25,000	875,251		Jun 25 04:12 PM
Gruber James R.	Officer	Jun 23 '26	Proposed Sale	33.23	25,000	830,874		Jun 23 04:32 PM
Adams Jennifer McKie	Director	Jun 17 '26	Option Exercise	3.78	50,000	189,000	50,000	Jun 17 05:08 PM
Adams Jennifer McKie	Director	Jun 17 '26	Sale	32.48	50,000	1,623,795	0	Jun 17 05:08 PM
Adams Jennifer McKie	Director	Jun 17 '26	Proposed Sale	32.37	50,000	1,618,500		Jun 17 11:43 AM
Gruber James R.	Officer	Jun 02 '26	Proposed Sale	27.00	3,117	84,163		Jun 02 04:48 PM
BRYNJELSEN SEAN	President & CEO	May 28 '26	Sale	31.88	120,000	3,825,717	833,694	May 29 04:16 PM
BRYNJELSEN SEAN	Director	May 28 '26	Proposed Sale	32.40	120,000	3,888,000		May 28 03:12 PM
Krempa David	Chief Business Officer	May 22 '26	Option Exercise	3.58	30,591	109,516	68,046	May 27 06:28 PM
Krempa David	Chief Business Officer	May 26 '26	Option Exercise	1.38	37,524	51,658	62,773	May 27 06:28 PM
Krempa David	Chief Business Officer	May 27 '26	Option Exercise	2.18	19,679	42,879	44,928	May 27 06:28 PM
Krempa David	Chief Business Officer	May 22 '26	Sale	33.39	42,797	1,428,816	25,249	May 27 06:28 PM
Krempa David	Chief Business Officer	May 26 '26	Sale	31.49	37,524	1,181,732	25,249	May 27 06:28 PM
Krempa David	Chief Business Officer	May 27 '26	Sale	31.47	19,679	619,375	25,249	May 27 06:28 PM
Krempa David	Officer	May 22 '26	Proposed Sale	35.00	100,000	3,500,000		May 22 04:24 PM
RIEDEL NORBERT G	Director	Apr 21 '26	Option Exercise	8.10	32,155	260,605	67,155	Apr 22 04:40 PM
Krempa David	Officer	Jan 14 '26	Proposed Sale	15.62	1,942	30,334		Jan 14 05:17 PM
Gruber James R.	Officer	Jan 14 '26	Proposed Sale	15.47	2,293	35,484		Jan 14 05:09 PM
BRYNJELSEN SEAN	Officer	Jan 14 '26	Proposed Sale	15.39	5,015	77,182		Jan 14 11:28 AM
Gruber James R.	Officer	Dec 12 '25	Proposed Sale	16.88	5,450	91,996		Dec 12 05:11 PM
BRYNJELSEN SEAN	Officer	Dec 12 '25	Proposed Sale	16.88	8,035	135,631		Dec 12 05:05 PM
Erdogan-Trinkaus Ipek	Officer	Dec 12 '25	Proposed Sale	16.91	99	1,674		Dec 12 04:50 PM
Krempa David	Officer	Dec 12 '25	Proposed Sale	16.88	7,545	127,360		Dec 12 04:46 PM

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

PresidentMr. Sean E. Brynjelsen

Chief Business OfficerMr. David C. Krempa

ConsultantMr. James R. Gruber CPA

Chief Commercial OfficerMs. Ipek Erdogan-Trinkaus

Chief Financial Officer & SecretaryMs. Judith M. Matthews

SNWV Sanuwave Health Inc daily Stock Chart

Peers: RCEL SMTI ORGO ELUT MDXG TELA ECOR ELMD TCMD CUPR

| Held by: VTI VXF QQQS IWC

Index	-
Market Cap	45.59M
Enterprise Value	56.92M
Income	14.31M
Sales	43.90M
Book/sh	0.32
Cash/sh	1.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	55
IPO	Sep 30, 2009

P/E	22.04
Forward P/E	-
PEG	-
P/S	1.04
P/B	16.36
P/C	4.86
P/FCF	10.83
EV/EBITDA	27.77
EV/Sales	1.30
Quick Ratio	0.89
Current Ratio	1.28
Debt/Eq	7.42
LT Debt/Eq	5.41
Option/Short	No / Yes

EPS (ttm)	0.24
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	38.05% 61.12%
EPS Y/Y TTM	119.59%
Sales Y/Y TTM	12.02%
EPS Q/Q	-1216.90%
Sales Q/Q	-4.18%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	- -

Insider Own	5.42%
Insider Trans	-18.55%
Inst Own	47.87%
Inst Trans	-15.44%
ROA	41.10%
ROE	-
ROIC	80.01%
Gross Margin	73.96%
Oper. Margin	1.54%
Profit Margin	32.60%
SMA20	2.97%
SMA50	10.68%
SMA200	-62.75%
Trades

Shs Outstand	8.60M
Shs Float	8.14M
Short Float	3.02%
Short Ratio	3.41
Short Interest	0.25M
52W High	36.20 -85.36%
52W Low	3.92 35.20%
Volatility	5.93% 7.07%
ATR (14)	0.36
RSI (14)	53.76
Beta	1.47
Rel Volume	0.00
Avg Volume	72.04K
Volume	0

Perf Week	2.51%
Perf Month	12.65%
Perf Quarter	-10.62%
Perf Half Y	-72.27%
Perf YTD	-82.24%
Perf Year	-83.25%
Perf 3Y	-21.48%
Perf 5Y	-88.22%
Perf 10Y	-92.48%
Recom	1.00
Target Price	40.00
Prev Close	5.30
Price	5.30
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Initiated	Northland Capital	Outperform	$55
Jul-29-25	Initiated	Roth Capital	Buy	$49

Aug-07-26 05:02PM	SANUWAVE Health Inc (SNWV) (Q2 2026) Earnings Call Highlights: Record Applicator Sales Offset ... (GuruFocus.com)
Aug-06-26 05:00PM	Sanuwave Announces Q2 FY2026 Financial Results (GlobeNewswire)
09:22AM	Earnings To Watch: SANUWAVE Health Inc (SNWV) Q2 2026 -- GF Value Sees 166% Upside (GuruFocus.com)
Jul-30-26 06:00PM	Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results (GlobeNewswire)
Jul-13-26 04:30PM	Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance (GlobeNewswire) +6.22%
08:00AM	Loading…
Jun-16-26 08:00AM	Sanuwave Health Updates Second Quarter 2026 Guidance (GlobeNewswire) -41.99%
May-13-26 07:01PM	SANUWAVE Health Inc (SNWV) Q1 2026 Earnings Call Highlights: Record Revenue Amid Market Challenges (GuruFocus.com) +18.08% -9.87%
May-12-26 05:00PM	Sanuwave Announces Revenues and Financial Results for Q1 FY2026 (GlobeNewswire)
May-06-26 05:00PM	Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results (GlobeNewswire)
Apr-16-26 05:00PM	Sanuwave Health Reports Preliminary Q1 2026 Revenue of $9.6-$9.7 Million, Up 3-4% Year-over-Year (GlobeNewswire) +14.37%
Mar-26-26 05:00PM	Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025 (GlobeNewswire) -5.42%
09:18AM	SANUWAVE Health Inc (SNWV) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Mar-20-26 01:30PM	Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results (GlobeNewswire)
Feb-05-26 09:43AM	Deep Sail Capital Partners' Investment Thesis for Sanuwave Health (SNWV) (Insider Monkey)
Jan-09-26 05:00AM	Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3-$13.4 Million, Up 29-30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue (GlobeNewswire)
06:00AM	Loading…
Dec-10-25 06:00AM	Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-25 06:00AM	Sanuwave Announces the Addition of UltraMIST to Healogics Group Purchasing Organization (GPO), iSupply (GlobeNewswire) -8.61%
Nov-07-25 07:35AM	Sanuwave Health Inc. (SNWV) Beats Q3 Earnings and Revenue Estimates (Zacks) +17.68%
06:00AM	Sanuwave Announces Q3 FY2025 Financial Results (GlobeNewswire)
Nov-06-25 07:40AM	Insulet (PODD) Q3 Earnings and Revenues Beat Estimates (Zacks)
Nov-05-25 07:35PM	MariMed Inc. (MRMD) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 05:40PM	Jushi Holdings Inc. (JUSHF) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 04:35PM	Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results (GlobeNewswire) -5.25%
05:00AM	CMS Publishes Final Rule for Calendar Year 2026 Physician Fee Schedule for UltraMIST Procedure (CPT code 97610) (GlobeNewswire)
Oct-30-25 10:00AM	Sanuwave Health Inc. (SNWV) to Report Q3 Results: Wall Street Expects Earnings Growth (Zacks) -7.95%
Oct-07-25 05:39AM	Sanuwave Health (SNWV) Surges 9.1%: Is This an Indication of Further Gains? (Zacks) -21.58%
01:00AM	SANUWAVE Health Inc (SNWV) Q3 2025 Earnings Call Highlights: Record Revenue Amid Market Challenges (GuruFocus.com)
Oct-06-25 04:01PM	Sanuwave Health Announces Preliminary Revenue Results for the Third Quarter 2025 (Ended September 30, 2025) (GlobeNewswire) +9.06%
Oct-02-25 08:18AM	3 Lesser-Known Healthcare Names With Major Upside in Store (MarketBeat)
Sep-26-25 07:00AM	Sanuwave Announces Strategic Debt Refinancing with New Credit Facility (GlobeNewswire)
03:05AM	Loading…
Aug-09-25 03:05AM	SANUWAVE Health Inc (SNWV) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Rising ... (GuruFocus.com)
Aug-08-25 06:00AM	Sanuwave Announces Q2 FY2025 Financial Results (GlobeNewswire) +15.85%
Aug-04-25 05:00PM	Sanuwave Will Host a Conference Call on August 8, 2025 at 8:30 AM (ET) to Present Q2 2025 Financial Results (GlobeNewswire)
Jul-22-25 04:05PM	Sanuwave Health to Present at Canaccord Genuity Growth Conference (GlobeNewswire) -7.73%
Jul-14-25 04:30PM	Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025) (GlobeNewswire) -7.99%
Jun-03-25 07:30AM	Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations (GlobeNewswire) +7.95%
May-30-25 12:41AM	SANUWAVE Health, Inc. (SNWV): A Bull Case Theory (Insider Monkey) -7.03%
May-28-25 04:10PM	Sanuwave Health Selected for Inclusion in Russell 2000 Index (GlobeNewswire)
04:05PM	Sanuwave Health Appoints Greg Bazar to Board of Directors (GlobeNewswire)
May-09-25 06:00AM	Sanuwave Announces Q1 FY2025 Financial Results (GlobeNewswire)
May-05-25 05:00PM	Sanuwave Will Host a Conference Call on May 9, 2025 at 8:30 AM (ET) to Present Q1 2025 Financial Results (GlobeNewswire)
Apr-30-25 05:10AM	Deep Sail Capital Partner Q1 2025 Investor Letter (Seeking Alpha)
Apr-08-25 08:30AM	SANUWAVE Health Announces Preliminary Revenue Results for the First Quarter 2025 (Ended March 31, 2025) (GlobeNewswire)
Mar-21-25 10:55AM	SANUWAVE Health, Inc. (SNWV) Q4 2024 Earnings Call Transcript (SeekingAlpha) +17.53%
06:00AM	SANUWAVE Announces Record Quarterly Revenues: Q4 FY2024 Financial Results (GlobeNewswire)
Mar-17-25 08:00AM	SANUWAVE Will Host a Conference Call on March 21, 2025 at 8:30 AM (ET) to Present Q4 and Full Year 2024 Financial Results (Business Wire) +10.43%
Mar-04-25 04:06PM	Sanuwave Health to Uplist to the Nasdaq Global Market (GlobeNewswire)
Feb-19-25 09:04AM	SANUWAVE Health to Participate in 37th Annual Roth Conference (GlobeNewswire)
Jan-13-25 07:35AM	SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) (NewMediaWire) +6.67%
07:30AM	SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales (NewMediaWire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Opaleye Management Inc.	10% Owner	Apr 30 '26	Sale	16.15	25,000	403,775	5,500	May 04 04:05 PM
Opaleye Management Inc.	10% Owner	May 01 '26	Sale	16.11	10,581	170,465	5,000	May 04 04:05 PM
Opaleye Management Inc.	10% Owner	Apr 28 '26	Sale	18.47	46,288	854,819	7,500	Apr 30 04:10 PM
Opaleye Management Inc.	10% Owner	Apr 29 '26	Sale	17.25	24,360	420,152	6,500	Apr 30 04:10 PM
Opaleye Management Inc.	10% Owner	Apr 17 '26	Sale	20.46	16,267	332,841	10,000	Apr 21 06:17 PM
Opaleye Management Inc.	10% Owner	Apr 21 '26	Sale	20.50	202	4,142	954,798	Apr 21 06:17 PM
MANCHESTER MANAGEMENT CO LLC	Director by Deputization	Dec 11 '25	Sale	31.28	13,500	422,277	70,499	Dec 15 05:22 PM
MANCHESTER MANAGEMENT CO LLC	Director by Deputization	Dec 12 '25	Sale	21.04	6,500	136,789	63,999	Dec 15 05:22 PM
MANCHESTER MANAGEMENT CO LLC	Director by Deputization	Dec 08 '25	Sale	30.75	125,400	3,856,050	881,390	Dec 10 09:21 PM
MANCHESTER MANAGEMENT CO LLC	Director by Deputization	Dec 09 '25	Sale	30.58	8,785	268,679	872,605	Dec 10 09:21 PM
MANCHESTER MANAGEMENT CO LLC	Director by Deputization	Dec 10 '25	Sale	30.39	8,625	262,129	863,980	Dec 10 09:21 PM
MANCHESTER MANAGEMENT CO LLC	Director by Deputization	Dec 08 '25	Sale	31.60	2,000	63,203	2,000	Dec 10 09:21 PM

SANUWAVE Health, Inc. is a medical device company providing directed energy products into the wound care space. It engages in the development and marketing of directed energy products that utilize ultrasound technology. The company was founded on May 6, 2004 and is headquartered in Eden Prairie, MN.

CEO & ChairmanMr. Morgan C. Frank

Chief Operating OfficerMr. Daniel Coyle

Executive Vice President of SalesMr. Timothy Wern

CFO & SecretaryMr. Peter Sorensen

Chief Technology OfficerDr. Christopher Cook Ph.D.

Peers: BLCO ANIP TARS OCUL ALC OCS EYPT OTLK ALDX KPRX

| Held by: VTI IWM VXF IWO DFAS XPH FESM VTWO SCHA IHE

Index	RUT
Market Cap	1.06B
Enterprise Value	1.27B
Income	-37.23M
Sales	275.59M
Book/sh	0.41
Cash/sh	2.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	373
IPO	Apr 24, 2007

P/E	-
Forward P/E	12.91
PEG	-
P/S	3.83
P/B	69.42
P/C	12.58
P/FCF	210.22
EV/EBITDA	47.19
EV/Sales	4.61
Quick Ratio	2.08
Current Ratio	2.24
Debt/Eq	19.79
LT Debt/Eq	19.72
Option/Short	Yes / Yes

EPS (ttm)	-1.00
EPS next Y	2.18
EPS next Q	0.19
EPS this Y	47.62%
EPS next Y	3072.74%
EPS next 5Y	-
EPS past 3/5Y	35.17% -1.53%
Sales past 3/5Y	45.39% 40.99%
EPS Y/Y TTM	-244.96%
Sales Y/Y TTM	21.05%
EPS Q/Q	-459.56%
Sales Q/Q	10.85%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	-157.27% 0.44%

Insider Own	15.18%
Insider Trans	0.07%
Inst Own	57.56%
Inst Trans	2.18%
ROA	-9.77%
ROE	-114.80%
ROIC	-11.82%
Gross Margin	73.28%
Oper. Margin	2.07%
Profit Margin	-13.51%
SMA20	-4.92%
SMA50	-17.72%
SMA200	-27.71%
Trades

Shs Outstand	37.48M
Shs Float	31.80M
Short Float	24.41%
Short Ratio	13.67
Short Interest	7.76M
52W High	54.85 -48.68%
52W Low	26.96 4.41%
Volatility	4.10% 4.52%
ATR (14)	1.38
RSI (14)	33.84
Beta	0.16
Rel Volume	0.00
Avg Volume	567.69K
Volume	0

Perf Week	-2.09%
Perf Month	-16.22%
Perf Quarter	-26.79%
Perf Half Y	-27.35%
Perf YTD	-42.55%
Perf Year	-27.62%
Perf 3Y	95.49%
Perf 5Y	189.01%
Perf 10Y	841.47%
Recom	1.00
Target Price	65.00
Prev Close	28.15
Price	28.15
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Initiated	Leerink Partners	Outperform	$45
Jul-11-25	Initiated	Cantor Fitzgerald	Overweight	$76
Jun-12-25	Initiated	BTIG Research	Buy	$62
Jun-10-25	Initiated	William Blair	Outperform
Feb-06-25	Initiated	H.C. Wainwright	Buy	$57
Dec-04-24	Reiterated	B. Riley Securities	Buy	$73 → $69
Apr-11-24	Initiated	Craig Hallum	Buy	$24
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Show Previous Ratings

Oct-05-26 07:00AM	Harrow Closes Acquisition of TYRVAYA (GlobeNewswire)
Sep-30-26 07:00AM	Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO (GlobeNewswire)
Sep-01-26 07:00AM	Harrow to Participate in Three Investor Conferences in September (GlobeNewswire)
Aug-20-26 07:00AM	Harrow Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections (GlobeNewswire)
Aug-11-26 03:01PM	Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... (GuruFocus.com)
05:50PM	Loading…
Aug-10-26 05:50PM	Harrow: Q2 Earnings Snapshot (Associated Press)
04:05PM	Harrow Announces Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-06-26 07:00AM	Harrow Acquires Global Rights to TYRVAYA, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease (GlobeNewswire)
Jul-27-26 07:00AM	Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 (GlobeNewswire)
Jul-20-26 08:00AM	Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 (GlobeNewswire)
07:00AM	Harrow Highlights Growing Clinical Evidence Supporting IHEEZO and BYOOVIZ at ASRS 2026 Annual Meeting (GlobeNewswire)
Jul-01-26 07:00AM	Samsung Bioepis Relaunches BYOOVIZ (ranibizumab-nuna) in the United States in Partnership with Harrow (Business Wire)
07:00AM	Harrow Announces Commercial Launch of BYOOVIZ in the United States (GlobeNewswire)
Jun-10-26 07:00AM	Harrow Re-Launches VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare (GlobeNewswire) +7.29%
May-27-26 07:00AM	Harrow to Present at William Blair's 46th Annual Growth Stock Conference (GlobeNewswire)
03:01PM	Loading…
May-12-26 03:01PM	Harrow Inc (HROW) Q1 2026 Earnings Call Highlights: Strong Product Demand Amid Revenue Challenges (GuruFocus.com) -23.69%
May-11-26 04:37PM	Harrow: Q1 Earnings Snapshot (Associated Press)
04:05PM	Harrow Announces First Quarter 2026 Financial Results (GlobeNewswire)
Apr-27-26 07:00AM	Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 (GlobeNewswire)
Apr-16-26 07:00AM	Harrow Announces the Issuance of J-Code for IOPIDINE 1% (GlobeNewswire)
Apr-14-26 10:30AM	LogiCare3PL Selected as Distribution Partner by Harrow (PR Newswire)
Mar-24-26 04:57PM	Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 (GlobeNewswire)
08:15AM	Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth (GlobeNewswire)
Mar-18-26 07:00AM	Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting (GlobeNewswire)
Mar-09-26 09:03PM	Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions (GuruFocus.com)
Mar-04-26 07:00AM	Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference (GlobeNewswire)
Mar-03-26 04:14PM	Why Harrow, An IBD 50 Stock Up 32% Since January, Just Crashed (Investor's Business Daily) -27.96%
11:18AM	Harrow Q4 Earnings Call Highlights (MarketBeat)
08:11AM	Why Is Eye-Disease-Focused Harrow Stock Falling Today? (Benzinga)
07:00AM	Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication (GlobeNewswire)
06:00PM	Loading…
Mar-02-26 06:00PM	Harrow (HROW) Misses Q4 Earnings Estimates (Zacks)
05:08PM	Harrow: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance (GlobeNewswire)
Feb-28-26 09:32AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-26-26 05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-24-26 10:00AM	Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Analysts Boost Profit Forecasts On Two Names. One Is A Data Center Play. (Investor's Business Daily)
Feb-23-26 02:20PM	Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout (Investor's Business Daily)
10:00AM	Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-18-26 07:00AM	Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 (GlobeNewswire)
Feb-17-26 06:01PM	Private Capital's Strategic Moves: ECN Capital Corp Exit Impacts Portfolio by -3.57% (GuruFocus.com) +5.98%
07:00AM	Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack Kits (GlobeNewswire)
Feb-04-26 01:07PM	Eye Care Stock Sees New Path After Guidance (Investor's Business Daily)
Feb-03-26 06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks) +5.10%
Feb-02-26 07:00AM	Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270-$280 Million, Marking Another Year of Strong Growth (GlobeNewswire) +9.67%
Jan-15-26 01:00PM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
08:55AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Dec-09-25 12:56PM	Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong (Investor's Business Daily)
Nov-24-25 07:00AM	Harrow to Present at Two Investor Conferences in December (GlobeNewswire)
Nov-18-25 07:00AM	Harrow Announces Closing of Acquisition of Melt Pharmaceuticals (GlobeNewswire)
Nov-14-25 05:03PM	Private Capital's Strategic Moves: Spotlight on Matthews International Corp (GuruFocus.com) +7.65%
Nov-11-25 02:01PM	Harrow Inc (HROW) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans (GuruFocus.com) +13.47%
Nov-10-25 04:31PM	Harrow: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Harrow Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 07:00AM	Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 (GlobeNewswire)
Oct-08-25 11:23AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey) -5.14%
Oct-06-25 07:00AM	ImprimisRx Announces Leadership Changes (GlobeNewswire) -7.20%
Sep-26-25 08:57AM	Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? (Benzinga)
07:00AM	Harrow to Acquire Melt Pharmaceuticals (GlobeNewswire)
Sep-25-25 04:05PM	Harrow Launches Harrow Access for All (HAFA) (GlobeNewswire)
Sep-15-25 07:00AM	Harrow Announces Agenda and Speakers for Investor & Analyst Day (GlobeNewswire) +8.63%
Sep-08-25 05:57PM	Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 (GlobeNewswire) +7.52%
08:00AM	Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 (GlobeNewswire)
Sep-02-25 04:07AM	Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea (Insider Monkey)
Aug-26-25 04:15AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Aug-15-25 12:20PM	Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock (Zacks)
10:00AM	Best Momentum Stock to Buy for August 15th (Zacks)
09:55AM	Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet (Zacks)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily) +9.62%
Aug-11-25 05:55PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second-Quarter 2025 Financial Results (GlobeNewswire)
09:23AM	Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:22AM	Harrow Inc (HROW) Q2 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Aug-06-25 07:00AM	Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference (GlobeNewswire)
Aug-04-25 10:00AM	Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) +7.01%
Jul-29-25 07:00AM	Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 (GlobeNewswire)
Jul-21-25 03:34PM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Jul-17-25 07:00AM	Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
07:00AM	Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
Jul-14-25 10:01AM	Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? (Zacks)
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly) +11.35%
Jul-06-25 04:15AM	William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating (Insider Monkey)
Jul-02-25 09:00AM	Are Options Traders Betting on a Big Move in Harrow Stock? (Zacks)
Jun-18-25 07:00AM	Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications (Business Wire)
Jun-09-25 07:00AM	Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals (Business Wire)
May-14-25 10:07AM	Jim Cramer on Harrow, Inc. (HROW) - "Eye Care's a Good Biz - If It Makes Money, Don't Walk Away Pre-Breakout" (Insider Monkey)
07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-10-25 03:03AM	Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Harrow Announces First-Quarter 2025 Financial Results (Business Wire)
09:32AM	Harrow Inc (HROW) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-07-25 10:28AM	What To Expect From Harrow Inc (HROW) Q1 2025 Earnings (GuruFocus.com)
May-05-25 07:00AM	Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 (Business Wire)
Apr-30-25 07:35AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-29-25 07:35AM	What Recession? I'm Swimming In Dividends (Seeking Alpha)
Apr-24-25 10:00AM	NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension) (PR Newswire) +5.20%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AMIR SHOJAEI	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Proposed Sale	40.00	11,250	450,000		Aug 21 06:32 PM
Shojaei Amir	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Option Exercise	35.96	11,250	404,550	11,250	Aug 17 05:47 PM
Shojaei Amir	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Sale	40.00	11,250	450,000	0	Aug 17 05:47 PM
Graves Adrienne L	Director	May 18 '26	Buy	31.07	1,000	31,070	1,000	May 19 07:00 AM
SILVERNAIL LAUREN P	Director	May 18 '26	Buy	31.00	1,000	31,000	1,000	May 19 07:00 AM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	May 14 '26	Buy	30.20	10,000	302,000	2,996,130	May 15 07:01 AM
BOLL ANDREW R.	PRESIDENT AND CFO	May 14 '26	Buy	29.90	3,500	104,650	814,679	May 15 07:00 AM
Opaleye Management Inc.	10% Owner	Mar 04 '26	Sale	39.67	138,263	5,485,184	59,428	Mar 05 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '26	Sale	39.15	60,309	2,361,242	63,691	Mar 05 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 27 '26	Sale	54.18	5,000	270,900	65,000	Mar 03 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 06 '26	Sale	53.35	20,000	1,066,914	70,000	Jan 08 04:05 PM
BOLL ANDREW R.	PRESIDENT AND CFO	Dec 12 '25	Option Exercise	3.95	60,000	237,000	837,844	Dec 16 08:50 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Dec 12 '25	Option Exercise	3.95	180,000	711,000	3,066,124	Dec 16 08:48 PM

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company's FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company's ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

CEOMr. Mark L. Baum J.D.

C.M.A.Mr. Andrew R. Boll C.F.A.

Pharm.D.Dr. Amir W. Shojaei Ph.D.

President & CEO of Harrow's ImprimisRx DivisionMr. Francis W. Mullery

Vice President of Investor Relations & CommunicationsMr. Michael D. Biega

Peers: MRVI DNA TWST CBUS A ABSI SEER TECH TKNO DHR

| Held by: VTI IWM VXF IWO IBB VTWO IWC FESM IWN BUSM

Index	RUT
Market Cap	143.45M
Enterprise Value	160.70M
Income	-30.72M
Sales	77.68M
Book/sh	0.36
Cash/sh	0.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	146
IPO	Apr 22, 2010

P/E	-
Forward P/E	-
PEG	-
P/S	1.85
P/B	3.63
P/C	2.59
P/FCF	-
EV/EBITDA	-
EV/Sales	2.07
Quick Ratio	2.99
Current Ratio	3.06
Debt/Eq	2.20
LT Debt/Eq	1.89
Option/Short	Yes / Yes

EPS (ttm)	-0.34
EPS next Y	-0.28
EPS next Q	-0.10
EPS this Y	24.86%
EPS next Y	26.36%
EPS next 5Y	39.03%
EPS past 3/5Y	0.62% -4.52%
Sales past 3/5Y	-20.22% 0.38%
EPS Y/Y TTM	58.70%
Sales Y/Y TTM	35.89%
EPS Q/Q	15.19%
Sales Q/Q	-2.69%
Earnings	Aug 11 AMC
EPS/Sales Surpr.	8.26% 7.89%

Insider Own	7.10%
Insider Trans	-0.20%
Inst Own	62.35%
Inst Trans	-1.89%
ROA	-23.79%
ROE	-69.36%
ROIC	-32.27%
Gross Margin	80.47%
Oper. Margin	-31.23%
Profit Margin	-39.55%
SMA20	-2.38%
SMA50	-8.94%
SMA200	-28.45%
Trades

Shs Outstand	109.51M
Shs Float	101.73M
Short Float	4.76%
Short Ratio	4.22
Short Interest	4.84M
52W High	2.98 -56.04%
52W Low	0.96 36.70%
Volatility	8.59% 6.46%
ATR (14)	0.09
RSI (14)	45.82
Beta	2.37
Rel Volume	0.00
Avg Volume	1.15M
Volume	0

Perf Week	-3.68%
Perf Month	-5.07%
Perf Quarter	-11.49%
Perf Half Y	-48.02%
Perf YTD	-19.63%
Perf Year	-48.83%
Perf 3Y	-22.94%
Perf 5Y	-95.60%
Perf 10Y	-70.56%
Recom	1.50
Target Price	6.14
Prev Close	1.31
Price	1.31
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-24	Downgrade	The Benchmark Company	Buy → Hold
Jun-03-24	Resumed	Jefferies	Buy	$5
May-30-24	Initiated	Cantor Fitzgerald	Overweight	$11
Feb-29-24	Upgrade	The Benchmark Company	Hold → Buy
Nov-07-23	Downgrade	The Benchmark Company	Buy → Hold
Aug-07-23	Downgrade	TD Cowen	Outperform → Market Perform	$21 → $4
May-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Resumed	Piper Sandler	Overweight	$35
Mar-02-22	Resumed	Cowen	Outperform
Apr-12-21	Initiated	Piper Sandler	Overweight	$32
Mar-01-21	Initiated	Stifel	Buy	$30
Feb-26-21	Reiterated	H.C. Wainwright	Buy	$21 → $26
Mar-10-20	Initiated	The Benchmark Company	Buy
Jan-17-19	Upgrade	First Analysis Sec	Neutral → Outperform	$12 → $19
May-16-18	Initiated	Stephens	Overweight	$16
Oct-13-17	Reiterated	H.C. Wainwright	Buy	$8 → $8.50
May-31-17	Initiated	Jefferies	Buy	$8
Jan-26-17	Downgrade	First Analysis Sec	Overweight → Equal-Weight	$5.50
Jan-04-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Jan-06-16	Initiated	H.C. Wainwright	Buy	$6

Show Previous Ratings

Sep-28-26 06:00AM	Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA (GlobeNewswire)
Sep-25-26 06:29PM	What Needs To Be True To Buy Twist Bioscience Stock Now? (Trefis)
Aug-27-26 09:00AM	Codexis to Participate in Cantor Global Healthcare Conference 2026 (GlobeNewswire)
Aug-12-26 01:02AM	Codexis Inc (CDXS) (Q2 2026) Earnings Call Highlights: Biocatalysis Growth and ECO Synthesis ... (GuruFocus.com) +8.11%
Aug-11-26 04:42PM	Codexis: Q2 Earnings Snapshot (Associated Press)
04:05PM	Loading…
04:05PM	Codexis Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-03-26 09:00AM	Codexis Appoints David Butler, PhD, to Strategic Advisory Board (GlobeNewswire)
Jul-28-26 09:00AM	Codexis to Report Second Quarter 2026 Financial Results on August 11 (GlobeNewswire)
Jul-23-26 11:47PM	Codexis Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -25.63%
04:13PM	Codexis Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-20-26 09:00AM	Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA (GlobeNewswire)
May-07-26 05:34PM	Codexis: Q1 Earnings Snapshot (Associated Press) +10.47%
04:05PM	Codexis Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-29-26 09:00AM	Codexis to share RNA manufacturing advances at TIDES USA (GlobeNewswire)
Apr-23-26 09:00AM	Codexis to Report First Quarter 2026 Financial Results on May 7 (GlobeNewswire)
11:01PM	Loading…
Mar-11-26 11:01PM	Codexis Inc (CDXS) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com) +34.65%
04:37PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results (GlobeNewswire)
Mar-07-26 08:03PM	Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf (MarketBeat)
Mar-05-26 07:45AM	Liquidia Corporation (LQDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks) +16.67%
Mar-04-26 10:06AM	Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis Manufacturing Platform (PR Newswire) +10.20%
Feb-26-26 09:55AM	Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-25-26 09:00AM	Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11 (GlobeNewswire)
Feb-24-26 08:50AM	Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-17-26 09:00AM	Codexis to Participate in TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-10-26 09:00AM	Codexis Achieves ISO 9001:2015 Certification (GlobeNewswire)
08:15AM	Incyte (INCY) Q4 Earnings Lag Estimates (Zacks)
Jan-07-26 09:00AM	Codexis Expands Reach of the ECO Synthesis Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics (PR Newswire)
Nov-11-25 09:35AM	Down 30% in 4 Weeks, Here's Why You Should You Buy the Dip in Codexis (CDXS) (Zacks)
Nov-10-25 09:00AM	Codexis Announces Signing of Lease for GMP Manufacturing Facility (GlobeNewswire)
12:02AM	Loading…
Nov-07-25 12:02AM	Codexis Inc (CDXS) Q3 2025 Earnings Call Highlights: Strategic Shifts and New Partnerships ... (GuruFocus.com) -16.95%
Nov-06-25 08:00PM	Codexis (CDXS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.35%
06:55PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:21PM	Codexis Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-05-25 08:15AM	EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-04-25 05:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Oct-29-25 09:58AM	Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis Manufacturing Platform for Therapeutic siRNA Manufacturing (PR Newswire) -6.56%
Oct-23-25 07:05AM	Codexis to Report Third Quarter 2025 Financial Results on November 6 (GlobeNewswire)
Aug-28-25 09:00AM	Codexis to Participate in Cantor Global Healthcare Conference (GlobeNewswire)
Aug-14-25 03:12AM	Codexis Inc (CDXS) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Initiatives (GuruFocus.com)
Aug-13-25 05:15PM	Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.64%
04:23PM	Codexis: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Second Quarter 2025 Financial Results (GlobeNewswire)
07:30AM	[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-12-25 03:00PM	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 07:30AM	Switch Bioworks Expands Leadership Team and Moves into New Facility to Accelerate Development of its Microbial Fertilizer Products (PR Newswire)
Aug-04-25 05:15PM	Vertex Pharmaceuticals (VRTX) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +5.58%
Aug-01-25 07:45AM	Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 04:05PM	Codexis to Report Second Quarter 2025 Financial Results on August 13 (GlobeNewswire)
May-22-25 07:00AM	Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA (GlobeNewswire) +5.13%
May-21-25 04:05PM	Codexis to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 01:03PM	Q1 2025 Codexis Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... (GuruFocus.com)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:39PM	Codexis: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-13-25 05:10PM	Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-12-25 05:45PM	Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +7.32%
May-07-25 07:00AM	Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting (GlobeNewswire)
Apr-30-25 04:05PM	Codexis to Report First Quarter 2025 Financial Results on May 14 (GlobeNewswire)
Apr-24-25 10:01AM	Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:15AM	NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-09-25 05:00PM	Codexis Announces Byron Dorgan to Retire from Board of Directors (GlobeNewswire) +17.26%
Apr-03-25 10:01AM	Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? (Zacks) -8.03%
Apr-01-25 07:00AM	Codexis Appoints Cynthia Collins to Board of Directors (GlobeNewswire) -6.69%
Mar-24-25 07:00AM	Codexis Announces First Revenue-Generating Contract for ECO Synthesis Manufacturing Services (GlobeNewswire) +20.39%
Mar-07-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -6.74%
Feb-28-25 11:02AM	Q4 2024 Codexis Inc Earnings Call (Thomson Reuters StreetEvents) -22.65%
02:36AM	Codexis Inc (CDXS) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Revenue Growth ... (GuruFocus.com)
Feb-27-25 06:35PM	Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.53%
05:36PM	Codexis: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 04:05PM	Codexis to Participate in TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-14-25 05:15PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +5.12%
Feb-13-25 04:05PM	Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th (GlobeNewswire)
Feb-06-25 04:05PM	Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board (GlobeNewswire)
Jan-16-25 04:05PM	Codexis Appoints Christos Richards to Board of Directors (GlobeNewswire)
Jan-10-25 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) -7.77%
Dec-06-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire) +15.22%
Nov-19-24 04:05PM	Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +8.14%
Nov-14-24 04:05PM	Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics (GlobeNewswire) -7.43%
Nov-12-24 04:05PM	Codexis Announces Appointment of Raymond De Vre, PhD, to Board of Directors (GlobeNewswire)
04:05PM	Codexis Announces Appointment of Raymond De Vr , PhD, to Board of Directors (GlobeNewswire)
Nov-11-24 04:05PM	Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics (GlobeNewswire)
Nov-08-24 04:05PM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Nov-04-24 04:05PM	Codexis to Participate in Upcoming Healthcare Conferences (GlobeNewswire) +9.46%
Nov-01-24 09:01AM	Codexis Inc (CDXS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Focus ... (GuruFocus.com) +11.46%
Oct-31-24 05:30PM	Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:23PM	Codexis: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Codexis Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-24-24 04:05PM	Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire) -7.27%
Oct-15-24 07:10AM	Codexis announces employment inducement grants (TipRanks) +5.28%
Oct-14-24 07:05AM	Codexis Announces New Employment Inducement Grants (GlobeNewswire)
Oct-10-24 04:05PM	Codexis to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire) +6.06%
Oct-09-24 05:56PM	Codexis Inc (CDXS) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Erbez Georgia	See Remarks	Oct 12 '26	Sale	1.36	6,335	8,619	60,475	Oct 14 05:19 PM
MOORE ALISON	President and CEO	Oct 12 '26	Sale	1.36	6,335	8,619	244,171	Oct 14 05:17 PM
Erbez Georgia	Officer	Oct 12 '26	Proposed Sale	1.36	6,335	8,619		Oct 13 04:32 PM
MOORE ALISON	Officer	Oct 12 '26	Proposed Sale	1.36	6,335	8,619		Oct 13 04:27 PM
De Vre Raymond	Director	Jun 11 '26	Sale	2.37	2,605	6,174	84,811	Jun 11 08:19 PM
Lutz Stefan	Chief Scientific Officer	Feb 24 '26	Sale	1.13	5,862	6,641	130,421	Feb 25 07:54 PM
Lutz Stefan	Officer	Feb 24 '26	Proposed Sale	1.17	5,280	6,178		Feb 23 08:08 PM
Lutz Stefan	Chief Scientific Officer	Feb 06 '26	Sale	1.31	2,492	3,257	136,283	Feb 09 04:07 PM
Erbez Georgia	See Remarks	Feb 06 '26	Sale	1.31	3,826	5,001	66,810	Feb 09 04:07 PM
MOORE ALISON	President and CEO	Feb 06 '26	Sale	1.31	3,826	5,001	250,506	Feb 09 04:06 PM
Norrett Kevin	Officer	Feb 06 '26	Proposed Sale	1.27	3,291	4,180		Feb 06 06:18 PM
Lutz Stefan	Officer	Feb 06 '26	Proposed Sale	1.27	2,460	3,124		Feb 06 06:15 PM
KEVIN NORRETT	Officer	Jan 16 '26	Proposed Sale	1.67	1,745	2,914		Jan 16 05:09 PM
Lutz Stefan	CSO	Jan 07 '26	Sale	1.70	4,685	7,950	138,775	Jan 08 06:51 PM
Norrett Kevin	Officer	Jan 07 '26	Proposed Sale	1.70	6,123	10,409		Jan 07 09:17 PM
Opaleye Management Inc.	10% Owner	Dec 01 '25	Sale	1.67	253,533	422,766	179,989	Dec 01 05:41 PM
Opaleye Management Inc.	10% Owner	Nov 28 '25	Sale	1.75	107,490	188,108	188,522	Dec 01 05:41 PM
Opaleye Management Inc.	10% Owner	Nov 26 '25	Sale	1.74	5,000	8,706	191,012	Dec 01 05:41 PM
WOLF DENNIS P	Director	Nov 21 '25	Sale	1.56	8,952	13,988	138,951	Nov 25 04:18 PM
DENNIS P WOLF	Officer	Nov 21 '25	Proposed Sale	1.56	8,952	13,988		Nov 21 04:51 PM
Opaleye Management Inc.	10% Owner	Nov 12 '25	Sale	1.96	192,459	376,924	196,012	Nov 14 04:15 PM
De Vre Raymond	Director	Nov 11 '25	Sale	1.74	1,413	2,459	87,416	Nov 13 04:16 PM
Opaleye Management Inc.	10% Owner	Nov 11 '25	Sale	1.80	548,211	986,451	223,461	Nov 12 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 10 '25	Sale	1.73	208,318	361,369	236,682	Nov 12 04:05 PM
Opaleye Management Inc.	10% Owner	Nov 07 '25	Sale	1.70	10,000	16,968	240,000	Nov 12 04:05 PM

Codexis, Inc. is an enzyme engineering company, which engages in technology solutions to improve therapeutics manufacturing. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

PresidentDr. Alison Moore Ph.D.

CFO & Chief Business OfficerMs. Georgia L. Erbez

Chief Scientific OfficerDr. Stefan Lutz Ph.D.

Senior Vice President of Sales & MarketingMr. Britton Jimenez

Senior VP & Head of Human ResourcesMs. Karen Frechou-Armijo

GRCE

Grace Therapeutics Inc

ACOG

Alpha Cognition Inc

SLGL

Sol-Gel Technologies Ltd

ETON

Eton Pharmaceuticals Inc

SNWV

Sanuwave Health Inc

HROW

Harrow Inc

CDXS

Codexis Inc

Upgrade your Finviz experience